Regulation of Src Family Kinases in Human Cancers

Table 1

Src inhibitors with other agents in clinical trials.

Drug	Phase	Tumor type	Combination agent
Dasatinib	II	Advanced-NSCLC/Colorectal/Pancreatic/HNSCC/Breast/SCLC/Melanoma	—
	II	Resectable NSCLC/HNSCC	Erlotinib
	I-II	Advanced NSCLC	Erlotinib
	I	Breast	Capecitabine
	I	Breast	Paclitaxel
	I-II	Prostate/castration resistant prostate cancer	Docetaxel
	I	Colon	FOLFOX6/Cetuximab
Saracatinib	II	Prostate/Pancreatic/Osteosarcoma/Soft tissue sarcoma/Melanoma/Gastration-resistant prostate cancer/Thymoma/Colorectal/HNSCC	—
	II	Advanced NSCLC/SCLC	Carboplatin/Paclitaxel
	I	Advanced solid tumor	Cediranib
	I-II	Pancreatic	Gemcitabine
	II	Ovarian	Carboplatin
	II	Prostate/Breast with bone metastasis	Zoledronic acid
Bosutinib	II	Breast	—
	II	Breast	Exemestane
	II	Breast	Letrozole/Capecitabine
	I-II	Advanced solid tumor	Capecitabine
XL228	I	Advanced solid tumor	—
KX2-391	I	Advanced solid tumor/Lymphoma	—
AZM475271	I-II	Pancreatic	—
XL999	I	Advanced solid tumor	—